ArticlePoultry science2026
Animal and human food safety of chromium propionate in layer hen diets.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to determine the animal and human food safety of KemTRACE® chromium propionate (Cr Prop) when supplemented to layer diets at 1 and 5 times the recommended level. Three-hundred 21-wk-old Hy-Line W-36 layer hens were randomly assigned to treatments consisting of: Cr Prop supplemented to provide 0, 0.20, or 1.0 mg Cr/kg diet. The study was conducted from 21 through 36 wk of age. Eggs were collected during wk 24, 28, 32, and 36 for egg quality measurements. Eggs were collected on d 0, 28, 56, 84, and 112 for Cr analysis. At the end of the study blood was collected from the wing vein for plasma biochemical measurements and samples of liver, breast muscle, kidney, and skin (with adhering fat) were then obtained for Cr analysis. In wk 21-24 ADFI and egg production were lower (P = 0.01) in hens receiving 1.0 mg Cr/kg compared to the other treatments. Egg production was not affected by treatment from wk 25 - 36. This suggests an adaptation to the high level of Cr over time. Over the entire 16-wk study, ADFI was greater (P = 0.01) for hens receiving 0.20 or 1.0 mg Cr/kg diet than controls and egg production was lower (P = 0.01) for hens supplemented with 1.0 mg Cr/kg compared with those in other treatments. Egg yolk color was lower (P = 0.03) for hens receiving 1.0 mg Cr. Other egg quality measurements were not affected by treatment. Hens supplemented with 0.20 mg Cr/kg had lower (P ˂ 0.05) plasma cholesterol, chloride, lipemic index, and bile acid concentrations than controls. Supplementation of 1.0 mg Cr/kg increased (P ˂ 0.05) liver Cr relative to the control treatment, but did not affect Cr concentrations in eggs, breast muscle, kidney, or skin with adhering fat. Tissue Cr concentrations were similar in hens receiving 0 or 0.20 mg Cr/kg. Results support the human food and animal safety of Cr Prop supplemention to layer diets for up to 16 wk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.